Clinical Trial Update: Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial (BIIRTH) is evaluating SBRT or SIRT with combination immunotherapy for locally advanced, unresectable hepatocellular carcinoma; enrollment is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Tuen Mun Hospital | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2, Phase 3 | Status: RECRUITING